BMO Capital raised the firm’s price target on Neurogene (NGNE) to $26 from $22 and keeps an Outperform rating on the shares. BMO notes that the initial analysis of the most recently dosed 5 patients with NGN-401 was able to demonstrate ferritin control with no patients surpassing the 500 ng/mL level of clinical concern for HLH, hemophagocytic lymphohistiocytosis, and the firm states that it has more confidence in the company’s ability to control reactions going forward, the analyst tells investors in a research note.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NGNE:
- Neurogene Highlights Gene Therapy Advancements in New Update
- Neurogene Reports Q1 2025 Financial Progress and Updates
- Optimistic Buy Rating for Neurogene Amid Favorable Market and Regulatory Conditions
- Promising Outlook for Neurogene’s NGN-401 Amid Favorable Regulatory Environment and Trial Precedents
- Short Report: Bears bite into Krispy Kreme after another weak earnings report